Ian Bothwell updates Zeo Scientifix (ZEOX) 13D, showing 40.2% voting control

Rhea-AI Filing Summary

Zeo Scientifix, Inc. insider Ian T. Bothwell filed Amendment No. 3 to his Schedule 13D, reporting beneficial ownership of 1,195,094 shares of common stock, or 14.7% of the class based on 7,777,441 shares outstanding as of March 16, 2026.

This total includes common shares, warrants and options held by Bothwell. He also holds 50 shares of Series C Preferred Stock that provide an additional 25.5% of the company’s total voting power, giving him combined voting power of 40.2%. Recent changes reflect equity awards under the company’s 2021 Equity Incentive Plan.

Insights

Corporate governance analyst

Filing confirms the CEO/CFO holds effective voting control via common and preferred equity.

Ian T. Bothwell, the CEO, CFO and a director of Zeo Scientifix, reports beneficial ownership of 1,195,094 common shares, equal to 14.7% of the class, based on 7,777,441 shares outstanding as of March 16, 2026.

In addition, he owns 50 shares of Series C Preferred Stock, which carry an extra 25.5% of total voting power. Taken together, his aggregate voting power is 40.2%, giving him substantial influence over shareholder decisions and board matters.

The filing notes recent equity awards under the 2021 Equity Incentive Plan, including stock options granted on May 8, 2025. Future changes in his stake would most likely be disclosed through additional ownership or insider filings as they occur.

Key Figures

Beneficial ownership: 1,195,094 shares Ownership percentage: 14.7% Shares outstanding: 7,777,441 shares +4 more

7 metrics

Beneficial ownership 1,195,094 shares Common stock beneficially owned as of Amendment No. 3 filing

Ownership percentage 14.7% Percent of common stock class based on 7,777,441 shares outstanding

Shares outstanding 7,777,441 shares Common stock outstanding as of March 16, 2026

Series C Preferred voting power 25.5% Additional voting power from 50 Series C Preferred shares

Total voting power 40.2% Aggregate voting power from common and Series C Preferred Stock

Series C Preferred shares 50 shares Series C Preferred Stock held by Ian Bothwell

Stock options grant 55,000 options Options granted on May 8, 2025 under 2021 Equity Incentive Plan

Key Terms

beneficially owns, Series C Preferred Stock, Schedule 13D, 2021 Equity Incentive Plan, +1 more

5 terms

beneficially owns financial

"As of the filing date of this Amendment No. 3, the Reporting Person beneficially owns 1,195,094 shares"

Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.

Series C Preferred Stock financial

"the Reporting Person holds 50 shares of Series C Preferred Stock which provides the Reporting Person with an additional 25.5% of the total voting power"

A Series C preferred stock is a specific class of ownership issued during a later funding round that gives holders priority over common shareholders for getting paid and receiving dividends, like having a reserved lane in traffic when money is distributed. It often includes agreed rights such as a fixed payout, protection against dilution, and the option to convert into common shares, so investors treat it as a mix of safety and upside potential.

Schedule 13D regulatory

"This Amendment No. 3 to the Statement on ("Amendment No. 3") filed with the Securities and Exchange Commission"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

2021 Equity Incentive Plan financial

"options to purchase 55,000 shares of common stock granted to the Reporting Person on May 8, 2025 under the Issuer's 2021 Equity Incentive Plan"

voting power financial

"representing 14.7% of the voting power based on 7,777,441 shares of common stock outstanding"

Voting power is the ability shareholders have to influence a company's major decisions—like electing the board, approving mergers, or changing corporate rules—based on the voting rights attached to the shares they hold. For investors it matters because greater voting power is like holding more keys to a building: it gives you a stronger say over management choices and the company’s strategy, which can affect future value and risk.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)

Zeo Scientifix, Inc.

(Name of Issuer)

Shares of Common Stock $0.001 Par Value and Series C Preferred Stock $.001 Par Value

(Title of Class of Securities)

68621D206

(CUSIP Number)

Ian T. Bothwell
3321 College Avenue, Suite 246
Davie, FL, 33314
888-963-7881

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

01/14/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 68621D206

1

Name of reporting person

IAN T BOTHWELL

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

SC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 1,195,094.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 1,195,094.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

1,195,094.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

14.7 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

The number of shares Beneficially Owned by the Reporting Person consists of 1,195,094 shares of common stock (including 87,500 shares of restricted stock vesting on July 14, 2026, 187,500 shares issuable upon exercise of warrants and 180,000 shares issuable upon exercise of options held by the Reporting Person) representing 14.7% of the voting power based on 7,777,441 shares of common stock outstanding as of March 16, 2026, as reported by the Issuer in its January 31, 2026 Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on March 17, 2026 and giving effect to the exercise of the warrants and options held by the Reporting Person. In addition, the Reporting Person holds 50 shares of Series C Preferred Stock which provides the Reporting Person with an additional 25.5% of the total voting power. Accordingly, the Reporting Person's aggregate voting power is equal to 40.2%.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Shares of Common Stock $0.001 Par Value and Series C Preferred Stock $.001 Par Value
(b)	Name of Issuer: Zeo Scientifix, Inc.
(c)	Address of Issuer's Principal Executive Offices: 3321 College Avenue, Suite 246, Davie, FLORIDA , 33314.
Item 1 Comment: This Amendment No. 3 to the Statement on Schedule 13D ("Amendment No. 3") filed with the Securities and Exchange Commission (the "SEC") on August 16, 2018 (the "Schedule 13D"), on behalf of Ian Bothwell (the "Reporting Person"), with respect to the common stock of Zeo ScientifiX, Inc. (the "Issuer"), is being filed pursuant to Rule 13d-2 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), to amend and supplement certain information set forth below in the items indicated. All capitalized terms used in this Amendment No. 3 and not otherwise defined herein have the meanings ascribed to such terms in the Schedule 13D and or Amendments No. 1 and No. 2 filed with the SEC on August 20, 2021 and January 7, 2025, respectively. Except as amended and supplemented herein, the Schedule 13D, including the definitions of capitalized terms not otherwise defined herein, remains in full force and effect.
Item 2.	Identity and Background
(a)	This Amendment No. 3 is being filed by the Reporting Person;
(b)	The Reporting Person's business address is 3321 College Avenue, Suite 246, Davie, Florida 33314;
(c)	The Reporting Person is employed as the Chief Executive Officer and Chief Financial Officer of the Issuer and serves as a director of the Issuer;
(d)	The Reporting Person has not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors);
(e)	The Reporting Person was not, during the last five years, a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws; and
(f)	The Reporting Person is a citizen of the United States.
Item 3.	Source and Amount of Funds or Other Consideration
	The additional shares of the Issuer's common stock held by the Reporting Person as reported in Item 5(c) of and elsewhere in this Amendment No. 3 represent (i) options to purchase 55,000 shares of common stock granted to the Reporting Person on May 8, 2025 under the Issuer's 2021 Equity Incentive Plan (the "Plan"); and (ii) 87,500 restricted shares of common stock issued to the Reporting Person on January 14, 2026 under the Plan which vest on July 14, 2026.
Item 4.	Purpose of Transaction
	The additional shares of the Issuer's common stock acquired by the Reporting Person as reported in Item 5(c) of and elsewhere in this Amendment No. 3, were issued to the Reporting Person as described in Item 3, above. The Reporting Person has no definite plan to acquire or dispose of additional shares of the Issuer's common stock in open market or private transactions, but may do so in the future, subject to compliance with the Exchange Act and the rules and regulations thereunder. In addition, while there is no definite plan to issue additional shares of the Issuer's common stock to the Reporting Person under one or more of the Issuer's equity incentive plans, the board of directors or a committee thereof may determine to issue awards of shares of common stock under such plans to the Reporting Person from time to time in the future. Except as set forth in the preceding paragraph, the Reporting Person has no plans or proposals which relate to or would result in: (a) The acquisition by any person of additional securities of the issuer, or the disposition of securities of the issuer; (b) Any additional extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the issuer; (f) Any other material change in the issuer's business or corporate structure including but not limited to, if the issuer is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by Section 13 of the Investment Company Act of 1940; (g) Changes in the issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the issuer by any person; (h) Causing a class of securities of the issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) A class of equity securities of the issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or (j) Any action similar to any of those enumerated above.
Item 5.	Interest in Securities of the Issuer
(a)	As of the filing date of this Amendment No. 3, the Reporting Person beneficially owns 1,195,094 shares of the common stock of the Issuer (including 87,500 shares of restricted stock vesting on July 14, 2026, 187,500 shares issuable upon exercise of warrants and 180,000 shares issuable upon exercise of options held by the Reporting Person), representing 14.7% of the class after giving effect to the exercise of warrants and options held by the Reporting Person (the Reporting Person also holds 50 shares of Series C Preferred Stock which provides the Reporting Person with an additional 25.5% of the total voting power of the Issuer);
(b)	The Reporting Person has sole power to vote or to direct the vote of, and sole power to dispose or to direct the disposition of all of the 1,195,094 shares; and
(c)	The Reporting Person has effected the following transactions in the class of securities reported on (the Issuer's common stock) since the most recent filing of Schedule 13D (ss.240.13d-101): Date Nature of the Transaction Number of Shares Price 05/08/2025 Grant of stock options under the Issuer's 2021 Equity Incentive Plan (the "Plan") 55,000 $0.00 01/14/2026 Grant of restricted shares under the Plan 175,000 $0.00
(d)	None.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	There are no contracts, arrangements, understandings or relationships (legal or otherwise) between the Reporting Person and any other person with respect to any securities of the Issuer.
Item 7.	Material to be Filed as Exhibits.
	None.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

IAN T BOTHWELL

Signature:	/s/ Ian T. Bothwell
Name/Title:	Ian T. Bothwell
Date:	05/15/2026

Comments accompanying signature:

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of the filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement: provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

FAQ

What does Ian Bothwell’s latest Schedule 13D/A disclose about Zeo Scientifix (ZEOX)?

The amendment discloses that Ian Bothwell, Zeo Scientifix’s CEO and CFO, now beneficially owns 1,195,094 common shares. It also highlights his Series C Preferred Stock holdings, which together give him 40.2% total voting power in the company’s shareholder decisions.

How many Zeo Scientifix (ZEOX) common shares does Ian Bothwell beneficially own?

Ian Bothwell beneficially owns 1,195,094 shares of Zeo Scientifix common stock. This figure includes shares underlying warrants, options and restricted stock, and represents 14.7% of the common share class based on 7,777,441 shares outstanding as of March 16, 2026.

What is Ian Bothwell’s total voting power in Zeo Scientifix (ZEOX) after this filing?

Ian Bothwell’s total voting power is 40.2% of Zeo Scientifix’s voting securities. He holds 14.7% of the common stock’s voting power plus an additional 25.5% through 50 shares of Series C Preferred Stock, giving him significant influence over corporate governance outcomes.

How do Zeo Scientifix’s Series C Preferred Stock shares affect control of ZEOX?

Fifty shares of Zeo Scientifix Series C Preferred Stock held by Ian Bothwell provide 25.5% of total voting power. Combined with his common stock holdings, this preferred stake helps concentrate voting control, enabling him to strongly influence or determine key shareholder-level decisions at the company.

What new equity awards to Ian Bothwell are described in the Zeo Scientifix (ZEOX) 13D amendment?

The amendment notes options to purchase 55,000 common shares granted on May 8, 2025 under the 2021 Equity Incentive Plan. It also references additional restricted common shares issued on January 14, 2026, further increasing the equity-based component of Bothwell’s compensation package.

Does Ian Bothwell state any concrete plans to buy or sell more Zeo Scientifix (ZEOX) shares?

The filing states he has no definite plan to acquire or dispose of additional Zeo Scientifix shares. However, it notes he may transact in the future in compliance with securities laws, and that the board may grant further equity awards under existing incentive plans.